par Kopylov, Uri;Hanzel, Jurij;Liefferinckx, Claire 
;De Marco, Davide;Imperatore, Nicola;Plevris, Nikolas;Baston-Rey, Iria;Harris, Richard J;Truyens, Marie;Domislovic, Viktor;Vavricka, Stephan;Biemans, Vince;Myers, Sally;Sebastian, Shaji;Ben-Horin, Shomron;González Lama, Yago;Gilletta, Cyrielle;Ariella, Bar-Gil Shitrit;Zelinkova, Zuzana;Weisshof, Roni;Storan, Darragh;Zittan, Eran;Farkas, Klaudia;Molnar, Tamas;Franchimont, Denis ;Cremer, Anneline ;Afif, Waqqas;Castiglione, Fabiana;Lees, Charles;Barreiro De Acosta, Manuel;Lobaton, Triana;Doherty, Glen;Krznaric, Zeljko;Pierik, Marieke;Hoentjen, Frank;Drobne, David
Référence Alimentary pharmacology & therapeutics, 52, 1, page (135-142)
Publication Publié, 2020-07-01
;De Marco, Davide;Imperatore, Nicola;Plevris, Nikolas;Baston-Rey, Iria;Harris, Richard J;Truyens, Marie;Domislovic, Viktor;Vavricka, Stephan;Biemans, Vince;Myers, Sally;Sebastian, Shaji;Ben-Horin, Shomron;González Lama, Yago;Gilletta, Cyrielle;Ariella, Bar-Gil Shitrit;Zelinkova, Zuzana;Weisshof, Roni;Storan, Darragh;Zittan, Eran;Farkas, Klaudia;Molnar, Tamas;Franchimont, Denis ;Cremer, Anneline ;Afif, Waqqas;Castiglione, Fabiana;Lees, Charles;Barreiro De Acosta, Manuel;Lobaton, Triana;Doherty, Glen;Krznaric, Zeljko;Pierik, Marieke;Hoentjen, Frank;Drobne, DavidRéférence Alimentary pharmacology & therapeutics, 52, 1, page (135-142)
Publication Publié, 2020-07-01
Article révisé par les pairs
| Résumé : | Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited. |
